Localized Prostate cancer in candidates for renal transplantation and recipients of a kidney transplant : The French Guidelines from CTAFU
Copyright © 2020 Elsevier Masson SAS. All rights reserved..
OBJECTIVE: To define guidelines for the management of localized prostate cancer (PCa) in kidney transplant (KTx) candidates and recipients.
METHOD: A systematic review (Medline) of the literature was conducted by the CTAFU to report prostate cancer epidemiology, screening, diagnosis and management in KTx candidates and recipients with the corresponding level of evidence.
RESULTS: KTx recipients are at similar risk for PCa as general population. Thus, PCa screening in this setting is defined according to global French guidelines from CCAFU. Systematic screening is proposed in candidates for renal transplant over 50 y-o. PCa diagnosis is based on prostate biopsies performed after multiparametric MRI and preventive antibiotics. CCAFU guidelines remain applicable for PCa treatment in KTx recipients with some specificities, especially regarding lymph nodes management. Treatment options in candidates for KTx need to integrate waiting time and access to transplantation. Current data allows the CTAFU to propose mandatory waiting times after PCa treatment in KTx candidates with a weak level of evidence.
CONCLUSION: These French recommendations should contribute to improve PCa management in KTx recipients and candidates, integrating oncological objectives with access to transplantation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:31 |
|---|---|
| Enthalten in: |
Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie - 31(2021), 1 vom: 11. Jan., Seite 4-17 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Recommandations françaises du Comité de transplantation de l’Association française d’urologie (CTAFU) : cancer de la prostate localisé chez le patient transplanté rénal ou en attente de transplantation |
|---|
| Beteiligte Personen: |
Culty, T [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cancer de la prostate |
|---|
| Anmerkungen: |
Date Completed 02.09.2021 Date Revised 02.09.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.purol.2020.04.027 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM319872629 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM319872629 | ||
| 003 | DE-627 | ||
| 005 | 20231225172358.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1016/j.purol.2020.04.027 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1066.xml |
| 035 | |a (DE-627)NLM319872629 | ||
| 035 | |a (NLM)33423746 | ||
| 035 | |a (PII)S1166-7087(20)30678-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Culty, T |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Localized Prostate cancer in candidates for renal transplantation and recipients of a kidney transplant |b The French Guidelines from CTAFU |
| 246 | 3 | 3 | |a Recommandations françaises du Comité de transplantation de l’Association française d’urologie (CTAFU) : cancer de la prostate localisé chez le patient transplanté rénal ou en attente de transplantation |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.09.2021 | ||
| 500 | |a Date Revised 02.09.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a OBJECTIVE: To define guidelines for the management of localized prostate cancer (PCa) in kidney transplant (KTx) candidates and recipients | ||
| 520 | |a METHOD: A systematic review (Medline) of the literature was conducted by the CTAFU to report prostate cancer epidemiology, screening, diagnosis and management in KTx candidates and recipients with the corresponding level of evidence | ||
| 520 | |a RESULTS: KTx recipients are at similar risk for PCa as general population. Thus, PCa screening in this setting is defined according to global French guidelines from CCAFU. Systematic screening is proposed in candidates for renal transplant over 50 y-o. PCa diagnosis is based on prostate biopsies performed after multiparametric MRI and preventive antibiotics. CCAFU guidelines remain applicable for PCa treatment in KTx recipients with some specificities, especially regarding lymph nodes management. Treatment options in candidates for KTx need to integrate waiting time and access to transplantation. Current data allows the CTAFU to propose mandatory waiting times after PCa treatment in KTx candidates with a weak level of evidence | ||
| 520 | |a CONCLUSION: These French recommendations should contribute to improve PCa management in KTx recipients and candidates, integrating oncological objectives with access to transplantation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Practice Guideline | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Cancer de la prostate | |
| 650 | 4 | |a Kidney transplantation | |
| 650 | 4 | |a Prostate cancer | |
| 650 | 4 | |a Transplantation rénale | |
| 650 | 4 | |a Waiting list | |
| 700 | 1 | |a Goujon, A |e verfasserin |4 aut | |
| 700 | 1 | |a Defortescu, G |e verfasserin |4 aut | |
| 700 | 1 | |a Bessede, T |e verfasserin |4 aut | |
| 700 | 1 | |a Kleinclauss, F |e verfasserin |4 aut | |
| 700 | 1 | |a Boissier, R |e verfasserin |4 aut | |
| 700 | 1 | |a Drouin, S |e verfasserin |4 aut | |
| 700 | 1 | |a Branchereau, J |e verfasserin |4 aut | |
| 700 | 1 | |a Doerfler, A |e verfasserin |4 aut | |
| 700 | 1 | |a Prudhomme, T |e verfasserin |4 aut | |
| 700 | 1 | |a Matillon, X |e verfasserin |4 aut | |
| 700 | 1 | |a Verhoest, G |e verfasserin |4 aut | |
| 700 | 1 | |a Tillou, X |e verfasserin |4 aut | |
| 700 | 1 | |a Ploussard, G |e verfasserin |4 aut | |
| 700 | 1 | |a Rozet, F |e verfasserin |4 aut | |
| 700 | 1 | |a Méjean, A |e verfasserin |4 aut | |
| 700 | 1 | |a Timsit, M-O |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie |d 1997 |g 31(2021), 1 vom: 11. Jan., Seite 4-17 |w (DE-627)NLM012649481 |x 1166-7087 |7 nnns |
| 773 | 1 | 8 | |g volume:31 |g year:2021 |g number:1 |g day:11 |g month:01 |g pages:4-17 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.purol.2020.04.027 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 31 |j 2021 |e 1 |b 11 |c 01 |h 4-17 | ||